GLP-1 Medications Show Promise in Menopause Weight Management, But Specific Research Gaps Remain
GLP-1 medications, such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), are gaining attention for their potential role in managing weight during menopause, according to Acibadem International. While no randomized trials have specifically studied GLP-1 medicines in menopausal women, subgroup data from broader trials suggest that women over 50 experience similar percentages of weight loss as younger adults. For instance, pivotal trials showed average weight loss of 15% to 21% over 68-72 weeks. An observational analysis in 2024 indicated that postmenopausal women taking semaglutide alongside hormone therapy lost more weight (16%) than those on semaglutide alone (12%). However, this finding is considered weak to moderate evidence due to the study's observational nature and small sample size. GLP-1s primarily work by reducing appetite, slowing stomach emptying, and regulating blood sugar, rather than directly affecting menopausal hormones.
